Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics, Safety and Tolerability of Long-acting Cabotegravir With rHuPH20 in Healthy Volunteers
NCT05418868Phase 1Recruiting
- Sponsor
- ViiV Healthcare
- Start
- Jun 2022
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cabotegravir, ENHANZE and rilpivirine in human immunodeficiency virus infection (HIV) (3 arms), sponsored by ViiV Healthcare. Primary endpoints: Maximum observed plasma concentration, Time of maximum observed plasma concentration and 8 more. Started Jun 2022; status: recruiting.
02
Drugs
cabotegravirENHANZErilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05418868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05418868.